Daniel Barrios

490 total citations
13 papers, 274 citations indexed

About

Daniel Barrios is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Daniel Barrios has authored 13 papers receiving a total of 274 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Daniel Barrios's work include HER2/EGFR in Cancer Research (7 papers), Gastric Cancer Management and Outcomes (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Daniel Barrios is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Gastric Cancer Management and Outcomes (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Daniel Barrios collaborates with scholars based in United States, United Kingdom and Spain. Daniel Barrios's co-authors include Evan Y. Yu, Philip R. Debruyne, Hendrik‐Tobias Arkenau, Erika Hamilton, Anthony M. D’Amelio, Valentina Boni, Matt D. Galsky, Charles L. Shapiro, Filippo de Braud and Zenta Tsuchihashi and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Daniel Barrios

13 papers receiving 272 citations

Peers

Daniel Barrios
Mariela A. Blum Murphy United States
Özlem Nuray Sever Türkiye
Honghai Dai China
Mélodie Tazdait France
Anna Ventriglia Italy
S. Lasserre Switzerland
Lorenza Marino Italy
Janine Mahoney United States
Zhongmin Maxwell Wang Australia
Lyudmila Zhukova Russia
Mariela A. Blum Murphy United States
Daniel Barrios
Citations per year, relative to Daniel Barrios Daniel Barrios (= 1×) peers Mariela A. Blum Murphy

Countries citing papers authored by Daniel Barrios

Since Specialization
Citations

This map shows the geographic impact of Daniel Barrios's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Barrios with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Barrios more than expected).

Fields of papers citing papers by Daniel Barrios

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Barrios. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Barrios. The network helps show where Daniel Barrios may publish in the future.

Co-authorship network of co-authors of Daniel Barrios

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Barrios. A scholar is included among the top collaborators of Daniel Barrios based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Barrios. Daniel Barrios is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
3.
Italiano, Antoine, Hossein Borghaei, Sanjay Popat, et al.. (2024). 118MO Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): Interim analysis of a phase Ib study. Immuno-Oncology Technology. 24. 100747–100747. 3 indexed citations
4.
Siena, Salvatore, Kanwal Raghav, Toshiki Masuishi, et al.. (2024). HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nature Communications. 15(1). 10213–10213. 15 indexed citations
5.
Raghav, Kanwal, Salvatore Siena, Atsuo Takashima, et al.. (2023). Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.. Journal of Clinical Oncology. 41(16_suppl). 3501–3501. 43 indexed citations
6.
7.
Raghav, Kanwal, Takayuki Yoshino, Rosine Guimbaud, et al.. (2022). Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).. Journal of Clinical Oncology. 40(4_suppl). TPS224–TPS224. 5 indexed citations
8.
Galsky, Matt D., Silvia Foti, Evan Y. Yu, et al.. (2022). Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).. Journal of Clinical Oncology. 40(6_suppl). 438–438. 73 indexed citations
9.
Raghav, Kanwal, Takayuki Yoshino, Rosine Guimbaud, et al.. (2021). Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).. Journal of Clinical Oncology. 39(15_suppl). TPS3620–TPS3620. 14 indexed citations
10.
Borghaei, Hossein, Benjamin Besse, Aditya Bardia, et al.. (2021). P01.02 Trastuzumab Deruxtecan Plus Pembrolizumab in Advanced/Metastatic Breast or Non-Small Cell Lung Cancer: A Phase 1b Study. Journal of Thoracic Oncology. 16(3). S236–S236. 2 indexed citations
11.
Hamilton, Erika, Charles L. Shapiro, Daniel P. Petrylak, et al.. (2021). Abstract PD3-07: Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study. Cancer Research. 81(4_Supplement). PD3–7. 47 indexed citations
12.
Borghaei, Hossein, Benjamin Besse, Aditya Bardia, et al.. (2020). Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.. Journal of Clinical Oncology. 38(15_suppl). TPS1100–TPS1100. 19 indexed citations
13.
Thibault, Constance, Karim Fizazi, Daniel Barrios, et al.. (2014). Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours. European Journal of Cancer. 50(7). 1284–1290. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mariela A. Blum Murphy Breakdown of academic impact, for papers by Özlem Nuray Sever Breakdown of academic impact, for papers by Honghai Dai Breakdown of academic impact, for papers by Mélodie Tazdait Breakdown of academic impact, for papers by Anna Ventriglia Breakdown of academic impact, for papers by S. Lasserre Breakdown of academic impact, for papers by Lorenza Marino Breakdown of academic impact, for papers by Janine Mahoney Breakdown of academic impact, for papers by Zhongmin Maxwell Wang Breakdown of academic impact, for papers by Lyudmila Zhukova
Rankless by CCL
2026